All Articles

DKN-01 plus tislelizumab and CAPOX combination demonstrates promising response rates and safety data in phase 2a study.

Nivolumab combined with chemotherapy had improved survival outcomes and an acceptable safety profile in patients with advanced gastric/esophageal cancer, according to CheckMate-649 study results.

A recently released MYLUNG study found that most patients with untreated metastatic NSCLC tested for ≥1 biomarkers, but <50% of patients had ≥5 biomarker tests.

Recently released clinical trial results evaluating the effect of early integration of interdisciplinary supportive care found improvement in quality of life, mood, and nutritional status in patients with NSCLC.

Caregivers and patients report better understanding of precision medicine and reduced patient anxiety with implementation of a therapeutic patient education program.

Study results reveal that KRAS G12C mutations vary according to sex and ethnicity in patients with cancer.

Nivolumab plus chemotherapy in patients with advanced gastric cancer, esophageal adenocarcinoma, or gastroesophageal junction cancer led to significantly higher health-related quality-of-life scores than in patients receiving chemotherapy alone.

KEYNOTE-590 study results demonstrate improved overall survival and progression-free survival across subgroups for treatment-naïve patients with advanced esophageal cancer receiving pembrolizumab combined with chemotherapy.

Patients with previously treated advanced or metastatic gastric cancer receiving sintilimab showed a modest response rate and an acceptable safety profile.